Literature DB >> 2147597

The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis.

R W Whitehouse1, J E Adams, K Bancroft, C A Vaughan-Williams, M Elstein.   

Abstract

Single and dual-energy quantitative computed tomography (QCT) were used to measure spinal trabecular bone mineral content in 24 women treated with either nafarelin (15 patients) or danazol (nine patients) for endometriosis. Significant loss of bone mineral (-9.6 g/l; -5.9% P less than 0.001) was demonstrated after 6 months' treatment with nafarelin. This loss was reversible with no significant difference in the bone mineral measurement made before treatment and that made at 6 months after treatment was stopped (difference -1.95 g/l, NS). A small but statistically significant (+2.2 g/l, P less than 0.05) increase in bone mineral was measured in the group of patients treated with danazol for 6 months. The dual-energy QCT gave similar results, indicating little change in trabecular fat content. A significant correlation was demonstrated between mean serum oestradiol levels during treatment with nafarelin and the change in bone mineral (r = 0.655, P less than 0.005).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2147597     DOI: 10.1111/j.1365-2265.1990.tb00501.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  9 in total

1.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

2.  Long-term effects on bone mineral density and bone metabolism of 6 months' treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate.

Authors:  Kazuya Makita; Ken Ishitani; Hiroaki Ohta; Fumi Horiguchi; Shiro Nozawa
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

3.  Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin.

Authors:  C Roux; C Pelissier; V Listrat; S Kolta; C Simonetta; M Guignard; M Dougados; B Amor
Journal:  Osteoporos Int       Date:  1995-05       Impact factor: 4.507

Review 4.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

Review 5.  Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density.

Authors:  M Sagsveen; J E Farmer; A Prentice; A Breeze
Journal:  Cochrane Database Syst Rev       Date:  2003

6.  Reduced bone mineral density in young adults following cure of acute lymphoblastic leukaemia in childhood.

Authors:  B M Brennan; A Rahim; J A Adams; O B Eden; S M Shalet
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

7.  Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist for Severe Endometriosis: Effects on Bone Mineral Density.

Authors:  Young Hwa Cho; Mi Jung Um; Suk Jin Kim; Soo Ah Kim; Hyuk Jung
Journal:  J Menopausal Med       Date:  2016-12-31

8.  Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study.

Authors:  Thomas D'Hooghe; Takao Fukaya; Yutaka Osuga; Robin Besuyen; Beatriz López; Gertjan M Holtkamp; Kentaro Miyazaki; Laurence Skillern
Journal:  Hum Reprod       Date:  2019-05-01       Impact factor: 6.918

Review 9.  The impact of sex steroids on osteonecrosis of the jaw.

Authors:  Ranhee Kim; Sung Woo Kim; Hoon Kim; Seung-Yup Ku
Journal:  Osteoporos Sarcopenia       Date:  2022-06-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.